Three-Year Follow-Up After Treatment of Coronary Artery Lesions Using Sirolimus-Coated Balloons: Insights From Real-World All-Comer Patients

被引：0

作者：

Dani, Sameer ^{[1
]}

Cortese, Bernardo ^{[2
]}

机构：

[1] Apollo Hosp Int, Ahmadabad, Gujarat, India

[2] San Carlo Clin, Milan, Italy

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2021年 / 78卷 / 19期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

TCT-447

引用

页码：B184 / B184

页数：1

共 50 条

[41] Comments on the article by Routledge et al "Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II)"
Latib, Azeem
Airoldi, Flavio
EUROINTERVENTION, 2010, 5 (07) : 875 - 876
[42] Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Stu
Wu JianQiu
Song YongPing
Su LiPing
Zhang MingZhi
Li Wei
Hu Yu
Zhang XiaoHong
Gao YuHuan
Niu ZuoXing
Feng Ru
Wang Wei
Peng JieWen
Li XiaoLin
Ouyang XueNong
Wu ChangPing
Zhang WeiJing
Zeng Yun
Xiao Zhen
Liang YingMin
Zhuang YongZhi
Wang JiShi
Sun ZiMin
Bai Hai
Cui TongJian
Feng JiFeng
Department of Oncology Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Nanjing Jiangsu China
Department of Hematology Henan Cancer Hospital Zhengzhou Henan China
Department of Hematology Shanxi Cancer Hospital Taiyuan Shanxi China
Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China
Department of Oncology Jilin University First Affiliated Hospital Changchun Jilin China
Department of Hematology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China
Department of Hematology The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China
Department of Hematology Fourth Hospital of Hebei Medical University Shijiazhuang Hebei China
Department of Oncology Affiliated Hospital of Shandong Academy of Medical Sciences Jinan Shandong China
Department of Hematology Medical University Nanfang Hospital Guangzhou Guangdong China
Department of Oncology Guangdong Foshan First Hospital Foshan Guangdong China
Department of Oncology Guangdong Zhongshan Peoples Hospital Zhongshan Guangdong China
Department of Hematology Xiangya Hospital Central South University Changsha Hunan China
Department of Oncology Fuzhou General Hospital of Nanjing Military Command Fuzhou Fujian China
Department of Oncology Changzhou First Peoples Hospital Changzhou Jiangsu China
Department of Oncology Hospital of Chinese Peoples Liberation Army Beijing Chinanow works at Department of Oncology Beijing Shijitan Hospital Capital Medical University Beijing China
Department of Hematology First Affiliated Hospital of Kunming Medical University Kunming Yunnan China
Department of Hematology Affiliated Hospital of Neimenggu Medical College Hohhot Huhehaote Inner Mongolia China
Department of Hematology The Fourth Military Medical University Affiliated Tangdu Hospital Xian Shaanxi China
Department of Oncology Daqing General Hospital Group Oilfield General Hospital Daqing Heilongjiang China
Department of Hematology Affiliated Hospital of Guiyang Medical College Guiyang Guizhou China
Department of Hematology Anhui Provincial Hospital Hefei Anhui China
Department of Hematology Lanzhou Military Hospital Lanzhou Gansu China
Department of Oncology Fujian Provincial Hospital Fuzhou Fujian China WeiJing Zhang now works at Department of Oncology Beijing Shijitan Hospital Capital Medical University Beijing China
中华医学杂志英文版, 2018, 131 (15) : 1767 - 1775
[43] Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study
Wu, Jian-Qiu
Song, Yong-Ping
Su, Li-Ping
Zhang, Ming-Zhi
Lis, Wei
Hu, Yu
Zhang, Xiao-Hong
Gao, Yu-Huan
Niu, Zuo-Xing
Feng, Ru
Wang, Wei
Peng, Jie-Wen
Li, Xiao-Lin
Ouyang, Xue-Nong
Wu, Chang-Ping
Zhang, Wei-Jing
Zeng, Yun
Xiao, Zhen
Liang, Ying-Min
Zhuang, Yong-Zhi
Wang, Ji-Shi
Sun, Zi-Min
Bai, Hai
Cui, Tong-Jian
Feng, Ji-Feng
CHINESE MEDICAL JOURNAL, 2018, 131 (15) : 1767 - 1775
[44] Comments on the article by Routledge et al "Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II)" Reply
Rutledge, Helen
Lefevre, Thierry
EUROINTERVENTION, 2010, 5 (07) : 876 - 876
[45] Discontinuation, switching, and other long-term real-world treatment patterns among patients with diabetic macular edema initiating anti-VEGF: 6-year follow-up using the IRIS® Registry
Kim, Eunice
Garmo, Vince
Tabano, David
Kuo, Blanche
Leng, Theodore
Hatfield, Meghan
LaPrise, Andrew
Singh, Rishi P.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
[46] Letter to the Editor Regarding "Ticagrelor for Asian Patients With Acute Coronary Syndrome in Real-World Practice: A Systematic Review and Meta-analysis of Observational Studies." The Benefit of Using Person-Year When the Follow-up Period Varies in a Meta-analysis
Kumar, Ashish U.
Shariff, Mariam
INDIAN HEART JOURNAL, 2019, 71 (02) : 176 - 177
[47] Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial
Stone, Gregg W.
Midei, Mark
Newman, William
Sanz, Mark
Hermiller, James B.
Williams, Jerome
Farhat, Naim
Caputo, Ronald
Xenopoulos, Nicholas
Applegate, Robert
Gordon, Paul
White, Roseann M.
Sudhir, Krishnankutty
Cutlip, Donald E.
Petersen, John L.
CIRCULATION, 2009, 119 (05) : 680 - 686
[48] Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
Caixeta, Adriano
Lansky, Alexandra J.
Serruys, Patrick W.
Hermiller, James B.
Ruygrok, Peter
Onuma, Yoshinobu
Gordon, Paul
Yaqub, Manejeh
Miquel-Hebert, Karine
Veldhof, Susan
Sood, Poornima
Su, Xiaolu
Jonnavithula, Lalitha
Sudhir, Krishnankutty
Stone, Gregg W.
JACC-CARDIOVASCULAR INTERVENTIONS, 2010, 3 (12) : 1220 - 1228
[49] RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND A LOW-INTERMEDIATE A PRIORI RISK OF CORONARY ARTERY DISEASE AFTER INITIAL CT-BASED DIAGNOSIS AND TREATMENT A REGISTRY-BASED FOLLOW-UP STUDY USING DATA FROM THE WESTERN DENMARK HEART REGISTRY
de Thurah, Annette
Andersen, Ina Trolle
Tinggaard, Andreas Bugge
Riis, Anders Hammerich
Therkildsen, Josephine
Botker, Hans Erik
Bottcher, Morten
Hauge, Ellen-Margrethe
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1392 - 1392
[50] Enlarge-Lung: Two-Year Follow-Up of Real-World Patients with Locally Advanced or Metastatic (Stage IIIB/IV) Squamous and Non-Squamous Non-Small Cell Lung Cancer (NSCLC) from a National, Prospective, Non-Interventional Study (NiS Enlarge) of Nivolumab after Prior Chemotherapy in Germany
Groeschell, Andreas
Schumann, Christian
Guetz, Sylvia
Schulz, Holger
Mueller-Huesmann, Harald
Schulte, Clemens
Liersch, Ruediger
von der Heyde, Eyck
Wuensch, Verena
Sebastian, Martin
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 117 - 118

← 1 2 3 4 5 →